Aurobindo Pharma gets US FDA nod for Alzheimer's drug Memantine Hydrochloride
Aurobindo Pharma said it has received final approval from the US FDA to manufacture and market Memantine Hydrochloride used in treatment of Alzheimer's. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 15, 2015 Category: Pharmaceuticals Source Type: news
Dr Reddy's launches generic dementia treatment tablets in US
Dr Reddy's Laboratories has launched in the US market the generic Memantine hydrochloride tablets used for treatment of dementia of the Alzheimer's type. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 13, 2015 Category: Pharmaceuticals Source Type: news
Dr Reddy's Laboratories launches generic dementia treatment tablets in US
Drug firm Dr Reddy's Laboratories has launched in the US market the generic Memantine hydrochloride tablets used for treatment of dementia. (Source: The Economic Times)
Source: The Economic Times - July 13, 2015 Category: Consumer Health News Source Type: news
Dementia Drug May Help Improve ADHD SymptomsDementia Drug May Help Improve ADHD Symptoms
Memantine, a drug used for the treatment of dementia, may help improve impaired executive function in adults with ADHD when used with standard stimulant therapy. Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - June 17, 2015 Category: Psychiatry Tags: Psychiatry News Source Type: news
Court Says No to Actavis Plan to Thwart Namenda Generics
A U.S. Court of Appeals has upheld a December decision declaring that Ireland-based Actavis must keep Namenda, it's dementia drug, on the market. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 28, 2015 Category: Pharmaceuticals Source Type: news
Business Briefing: Court Bars Removal of Cheaper Alzheimer’s Drug
A federal appeals court in New York ruled on Friday that Actavis cannot withdraw its top-selling Alzheimer’s disease drug from the market in favor of a more expensive extended-release version. (Source: NYT Health)
Source: NYT Health - May 22, 2015 Category: Consumer Health News Authors: REUTERS Tags: Alzheimer's Disease Actavis PLC ACT NYSE Drugs (Pharmaceuticals) Suits and Litigation (Civil) Namenda XR Antitrust Laws and Competition Issues New York State Namenda IR Source Type: news
Battle Over Namenda Swap Has Big Stakes for Drugmakers, Consumers
(MedPage Today) -- At issue: an aggressive, some say unethical and illegal, drug sales tactic. (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - March 20, 2015 Category: Psychiatry Source Type: news
Namzaric (Memantine/Donepezil) for the Treatment of Alzheimer's Disease
Namzaric (memantine/donepezil) is the first fixed-dose combination drug approved for the treatment of moderate and severe Alzheimer's disease in the US. (Source: Drug Development Technology)
Source: Drug Development Technology - February 17, 2015 Category: Pharmaceuticals Source Type: news
Namzaric (Memantine Hydrochloride Extended-release and Donepezil Hydrochloride Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 2, 2015 Category: Drugs & Pharmacology Source Type: news
Judge delivers blow to maker of Alzheimer's drug
The maker of the Alzheimer's drug Namenda announced it would stop selling the drug and was moving patients to a newer version called
Namenda XR. But New York's attorney general filed a lawsuit, saying the practice blocked competition and was illegal. Dr. Jon LaPook has the latest developments. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - January 1, 2015 Category: Consumer Health News Source Type: news
Judge makes ruling in Alzheimer's drug case
A lawsuit claimed the makers of Namenda were trying to avoid competition from cheaper generic drugs (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - January 1, 2015 Category: Consumer Health News Source Type: news
FDA OKs Namzaric Combo Pill for Alzheimer's DiseaseFDA OKs Namzaric Combo Pill for Alzheimer's Disease
The memantine/donepezil combination offers a once-daily fixed-dose combination of two treatments often prescribed together in one capsule. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 27, 2014 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news
Actavis and Adamas Announce FDA Approval of Namzaric(TM), a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride
Indicated for Treatment of Moderate to Severe Alzheimer's Disease
DUBLIN and EMERYVILLE, Calif., Dec. 24, 2014 -- (Healthcare Sales & Marketing Network) -- Actavis plc (ACT) and Adamas Pharmaceuticals Inc. (ADMS) today announced that the U.S. Food and ... Biopharmaceuticals, Neurology, FDAActavis , Adamas Pharmaceuticals, Namzaric, Alzheimer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 24, 2014 Category: Pharmaceuticals Source Type: news
Actavis' Stance On Namenda Is Harming Pharma's Image
Discontinuation of Namenda in order to boost sales of the XR version reinforces all of the bad views that people have of the pharmaceutical industry and provides great fodder for its critics. Actavis has joined the “Big Pharma” club. It would be nice if it became part of the solution to Big Pharma’s image woes, rather than adding to the problem. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 17, 2014 Category: Pharmaceuticals Authors: John LaMattina Source Type: news
Study finds Alzheimer's drug may reduce the urge to binge eat
(Boston University Medical Center) The Alzheimer's drug memantine may perform double-duty helping binge eaters control their compulsion. Researchers have demonstrated that memantine, a neuroprotective drug, may reduce the addictive and impulsive behavior associated with binge eating. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - November 13, 2014 Category: Global & Universal Source Type: news
